Mayo Clinic | Strategic Alliance Partners

February 17, 2017

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses the use of PD-1 inhibitors for patients with Hodgkin lymphoma.

February 08, 2017

Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses some future treatment approaches for patients with aggressive lymphomas, including diffuse large B-cell lymphoma.

January 26, 2017

Charles L. Loprinzi, MD may have landed somewhat accidentally into the world of symptom management research, but once he arrived, he was there to stay.

January 24, 2017

Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses combination regimens that seem promising and are under investigation in the treatment landscape of chronic lymphocytic leukemia.

January 24, 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the safety profile and the survival benefits associated with venetoclax in the treatment of patients with multiple myeloma.

January 20, 2017

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses the FDA approval of of ibrutinib (Imbruvica) as a treatment for patients with marginal zone lymphoma (MZL).

January 19, 2017

A direct assessment of the uterine microbiome in patients with endometrial cancer has revealed a potential predictive role for vaginal microbes.

January 12, 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses immunotherapeutic options being explored in the treatment landscape of colorectal cancer (CRC) beyond PD-1/PD-L1 agents.

December 26, 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the rationale for investigating venetoclax as a treatment for patients with multiple myeloma.

December 23, 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with colorectal cancer.

December 23, 2016

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses studies exploring PD-1 inhibitors in Hodgkin lymphoma, specifically the CheckMate-039 trial.

December 16, 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the recent expansion of treatment options available for patients with colorectal cancer.

December 14, 2016

The NCCN recently published new guidelines for myeloproliferative neoplasms (MPNs), with an emphasis on diagnosis, treatment, and supportive care strategies for myelofibrosis. Subsequent editions will focus more on other MPNs, including essential thrombocythemia, polycythemia vera.

December 14, 2016

Treatment for patients with aggressive lymphomas needs to be intensified with more effective strategies, potentially including an infusion, dose-adjusted regimen of etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride, and rituximab.

December 03, 2016

Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses updates that are expected in 2017 to the NCCN Guideline for Myeloproliferative Neoplasms (MPNs).

November 23, 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses his vision for the future treatment landscape of multiple myeloma.

November 22, 2016

Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discuses the recent FDA approval of daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

November 22, 2016

Investigators are exploring therapy options for patients with indolent lymphomas—including follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma—as rituximab regimens are proving to not be a long-term option for many patients.

November 21, 2016

Standard treatment approaches for patients with chronic lymphocytic leukemia will continue to include fludarabine, cyclophosphamide, and rituximab and allogeneic stem cell transplantation.

October 26, 2016

Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses treatment-related advances in the field of chronic lymphocytic leukemia (CLL) over the last several decades in an interview during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.